Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?ORRELL, Catherine; COHEN, Karen; CONRADIE, Francesca et al.Antiviral therapy (London). 2011, Vol 16, Num 4, pp 527-534, issn 1359-6535, 8 p.Article

High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South AfricaFOX, Matthew P; IVE, Prudence; LONG, Lawrence et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 4, pp 500-506, issn 1525-4135, 7 p.Article

Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan AfricaSIGALOFF, Kim C. E; HAMERS, Raph L; STEVENS, Wendy S et al.The Journal of infectious diseases. 2012, Vol 205, Num 11, pp 1739-1744, issn 0022-1899, 6 p.Article

Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovirBRENNAN, Alana; EVANS, Denise; MASKEW, Mhairi et al.AIDS (London). 2011, Vol 25, Num 13, pp 1603-1609, issn 0269-9370, 7 p.Article

Effect of pulmonary tuberculosis on mortality in patients receiving HAARTWESTREICH, Daniel; MACPHAIL, Patrick; VAN RIE, Annelies et al.AIDS (London). 2009, Vol 23, Num 6, pp 707-715, issn 0269-9370, 9 p.Article

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyLUETKEMEYER, Anne F; ROSENKRANZ, Susan L; HAVLIR, Diane V et al.Clinical infectious diseases. 2013, Vol 57, Num 4, pp 586-593, issn 1058-4838, 8 p.Article

Natural Killer Cell Activation Distinguishes Mycobacterium tuberculosis―Mediated Immune Reconstitution Syndrome From Chronic HIV and HIV/MTB CoinfectionCONRADIE, Francesca; FOULKES, Andrea S; AZZONI, Livio et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 3, pp 309-318, issn 1525-4135, 10 p.Article

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsGATHE, Joseph C; IVE, Prudence; WOOD, Robin et al.AIDS (London). 2004, Vol 18, Num 11, pp 1529-1537, issn 0269-9370, 9 p.Article

Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV TransmissionVARDHANABHUTI, Saran; ACOSTA, Edward P; SAMBAREY, Pradeep et al.The Journal of infectious diseases. 2013, Vol 208, Num 4, pp 662-671, issn 0022-1899, 10 p.Article

Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisHAVLIR, Diane V; KENDALL, Michelle A; HOSSEINIPOUR, Mina C et al.The New England journal of medicine. 2011, Vol 365, Num 16, pp 1482-1491, issn 0028-4793, 10 p.Article

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South AfricaFOX, Matthew P; SANNE, Ian M; WOOD, Robin et al.AIDS (London). 2010, Vol 24, Num 13, pp 2041-2050, issn 0269-9370, 10 p.Article

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsCOOPER, David A; HEERA, Jayvant; SAAG, Michael et al.AIDS (London). 2014, Vol 28, Num 5, pp 717-725, issn 0269-9370, 9 p.Article

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort studyHAMERS, Raph L; SCHUURMAN, Rob; OSIBOGUN, Akin et al.Lancet. Infectious diseases (print). 2012, Vol 12, Num 4, pp 307-317, issn 1473-3099, 11 p.Article

Low rates of nucleoside reverse transcriptase inhibitor resistance in a well―monitored cohort in South Africa on antiretroviral therapyWALLIS, Carole L; PAPATHANASOPOLOUS, Maria A; STEVENS, Wendy et al.Antiviral therapy (London). 2012, Vol 17, Num 2, pp 313-320, issn 1359-6535, 8 p.Article

Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART StrategiesHAMERS, Raph L; SIGALOFF, Kim C. E; OSIBOGUN, Akin et al.Clinical infectious diseases. 2012, Vol 54, Num 11, pp 1660-1669, issn 1058-4838, 10 p.Article

Early Warning Indicators for Population-Based Monitoring of HIV Drug Resistance in 6 African CountriesSIGALOFF, Kim C. E; HAMERS, Raph L; OSIBOGUN, Akin et al.Clinical infectious diseases. 2012, Vol 54, issn 1058-4838, S294-S299, SUP4Article

Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in AfricaSIGALOFF, Kim C. E; HAMERS, Raph L; STEVENS, Wendy S et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 1, pp 23-31, issn 1525-4135, 9 p.Article

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 InfectionCOOPER, David A; HEERA, Jayvant; REEVES, Jacqueline D et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 803-813, issn 0022-1899, 11 p.Article

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trialSANNE, Ian; ORRELL, Catherine; RASSOOL, Mohammed et al.Lancet (British edition). 2010, Vol 376, Num 9734, pp 33-40, issn 0140-6736, 8 p.Article